Actively Recruiting
Phase 1 Study Evaluating Safety and Dose of KIVU-107 in Adults With Advanced or Metastatic Solid Tumors
Led by Kivu Bioscience Inc. · Updated on 2026-09-24
76
Participants Needed
7
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in adults with locally advanced or metastatic solid tumors for which no effective standard therapy exists. This first-in-human, open-label trial includes participants with measurable disease and good organ function, aiming to find a suitable dosing level and confirm its safety. The study has two parts. In Part A, participants receive increasing doses of KIVU-107 given intravenously to determine the maximum tolerated dose and the recommended dose for expansion. In Part B, participants are treated with the dose identified in Part A to further assess safety and tolerability. The treatment is given in sequential cohorts without randomization or placebo. Participants will be monitored regularly for up to 30 months for safety, treatment-related side effects, and tumor response according to RECIST criteria. Blood samples will be taken to assess drug levels and immune response. Researchers will track the duration and quality of tumor response along with other pharmacokinetic measures. The total study duration allows close safety observation and response evaluation throughout the treatment period.
CONDITIONS
Brief Title
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Research Team
K
Kivu Bioscience (US)
K
Kivu Bioscience (Australia)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here